Upload
wing-richards
View
22
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Faculty. Panelists. Disclosures. Disclosures (cont). Target Audience and Learning Objectives. Metastatic Colorectal Cancer (mCRC). mCRC: Resectable. mCRC: (R)evolution. mCRC: (R)evolution (cont). mCRC: Approved/Investigational Drugs. mCRC: Past, Present, and Future. - PowerPoint PPT Presentation
Citation preview
Faculty
Panelists
Disclosures
Disclosures (cont)
Target Audience and Learning Objectives
Metastatic Colorectal Cancer (mCRC)
mCRC: Resectable
mCRC: (R)evolution
mCRC: (R)evolution (cont)
mCRC: Approved/Investigational Drugs
mCRC: Past, Present, and Future
mCRC: Targeted Therapy — Anti-Angiogenic
mCRC: Targeted Therapy — Anti-EGFR Biomarkers
mCRC: RAS Mutation Status
mCRC: Case Example
mCRC: Chemotherapy for Diffuse Metastatic Disease
mCRC: Chemotherapy for Diffuse Metastatic Disease cont
mCRC: Current Options for Addition of Biological Agent
mCRC: Treatment Options According to Clinical Criteria
mCRC: Which Frontline Regimen Should Be Used?
mCRC: Treatment Strategy
mCRC: Case Example: Progressing Disease With First- and Second-line
Therapy
Angiogenesis and Cancer: Rebound Effect
Anti-Angiogenesis and mCRC: Beyond Progression
Anti-angiogenesis and mCRC: Beyond Progression (Preclinical
Studies)
Anti-angiogenesis and mCRC: Beyond Progression
(preclinical data)
Anti-angiogenesis and mCRC: Beyond Progression (Clinical Data)
mCRC Strategies: Consolidation/Maintenance
Treatment
Consolidation/Maintenance Treatment — Timing and Efficacy
Consolidation/Maintenance Treatment — CAIRO3
Biomarker Status Over Time
mCRC: Serial Biomarker Testing
mCRC: Metabolic Imaging
mCRC: Liquid Biopsy - Following Changes in Genomic Status
mCRC: Dynamic Biomarker Study (UK)
Team Approach to Oncologic Therapy
Case Presentation, Part 1
Patient Case, Part 1: History
Patient Case, Part 1: Presentation and Findings
Patient Case, Part 1: Imaging and Laboratory Findings
Patient Case, Part 1: Clinical Considerations
Patient Case, Part 1: Treatment Options
Patient Case, Part 1: Initial Treatment and Instructions
Patient Case, Part 1: Response to Treatment
Patient Case, Part 1: Progression on Maintenance Therapy
Discussion (Part 1)Fortunato Ciardiello, MD; Marc
Peeters, MD, PhD
Case Presentation, Part 2
Patient Case, Part 2: First Relapse
Patient Case, Part 2: Laboratory Findings
Patient Case, Part 2: Patient Goals and Clinical Considerations
Patient Case, Part 2: Treatment Options
Patient Case, Part 2: Treatment and Patient Instructions
Patient Case, Part 2: FOLFIRI + Ziv-Aflibercept — Response
Discussion (Part 2)Fortunato Ciardiello, MD; Marc
Peeters, MD, PhD
Case Presentation, Part 3
Patient Case, Part 3: Disease Progression — Considerations
Patient Case, Part 3: Disease Progression — Considerations
Patient Case, Part 3: Disease Progression — Oxaliplatin…Again?
Patient Case, Part 3: Disease Progression — Local Therapies?
Patient Case, Part 3: Disease Progression — Regorafenib?
Patient Case, Part 3: Regorafenib - Administration
Patient Case, Part 3: Regorafenib - Administration
Discussion (Part 3) Fortunato Ciardiello, MD; Marc
Peeters, MD, PhD
Team Approach to Oncologic Therapy
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)